FDA has denied approval to market the drug, Bronchitol, manufactured by the Australian biotechnology company, Pharmaxis, in US market.
The dry powder formulation of mannitol (Bronchitol) is designed to treat cystic fibrosis. It is approved in Australia for patients above six years of age and for adults above 18 years old in European Union.
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care.
Advertisement
The review committee has rejected the approval stating that an additional trial is required to prove the efficacy of the drug. FDA has noted that the first two clinical trial data submitted by the company do not meet benefit- risk balance. The first trial had too many early dropouts while the second study failed to produce statistically significant results.
Gary Phillips, CEO of Pharmaxis has announced that the company is ready to work with FDA and take the required measured to gain approval.
Source: Medindia
Source: Medindia
Extensive Study Probes New Concerns on Antibiotic Use for Cystic Fibrosis
When concerning treating cystic fibrosis, the existing standard of aggressive antibiotic treatments may not at all times be the best answer, discovers a decade-long study led by researchers.
Advertisement
 People With Cystic Fibrosis Who Live in Deprived Areas Have Worse HealthPeople with Cystic Fibrosis (CF) who live in deprived areas have worse growth and lung function than people living in more advantaged areas, finds a study by the University of Liverpool. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
